The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation

The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation

Background. Potential adverse effects, such as functional impairment of islets, render conventional immunosuppressive drugs unsuitable for use in islet transplantation. In addition, as a single therapy, they cannot prolong islet allograft survival. Here, we investigated the utility of the mitogen-ac...

Full description

Bibliographic Details
Main Authors: Seiichiro Tada, MD, Takayuki Anazawa, MD, PhD, Takero Shindo, MD, PhD, Kei Yamane, MD, Kenta Inoguchi, MD, Nanae Fujimoto, MSc, Kazuyuki Nagai, MD, PhD, Toshihiko Masui, MD, PhD, Hideaki Okajima, MD, PhD, Kyoichi Takaori, MD, PhD, Shoichiro Sumi, MD, PhD, Shinji Uemoto, MD, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2020-09-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001045

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001045

Similar Items